Matched-Control Studies for Pharma Campaigns, Explained
How matched-control studies work for pharma campaigns: comparison groups, matching variables, balance checks, limits, and reading results.
The short answer
A matched-control study estimates a campaign's effect by comparing people or HCPs who were exposed with similar people or HCPs who were not, matched on factors that predict the outcome, such as prior prescribing, specialty, and region. It is common in pharma because randomized holdouts are not always possible. Its weakness is that unmeasured differences between groups can bias results, so balance checks and sensitivity analysis matter.
Many pharma outcome studies are matched-control designs. Vendors use them to measure point-of-care, programmatic, and DTC campaigns. Knowing how they work helps you ask the right questions and read results correctly.
The idea
Exposed HCPs or patients are not random. They were targeted for a reason, often because they were more likely to prescribe or have the condition. Comparing them with everyone else would overstate impact. Matching finds unexposed counterparts who were similar before the campaign.
Matching variables for HCP studies
- Prior prescribing of the brand and class.
- Patient volume in the condition.
- Specialty and practice type.
- Region.
- Exposure to other channels, such as rep calls.
- Prescribing trend before the campaign.
Matching methods
| Method | How it works | Notes |
|---|---|---|
| Exact matching | Pair on identical values of key variables | Simple, can discard many units |
| Propensity score matching | Model likelihood of exposure, match on score | Common; depends on model quality |
| Weighting | Reweight control group to match exposed group | Uses more data |
| Difference-in-differences | Compare changes over time between groups | Adjusts for stable differences |
Balance checks
After matching, compare groups on every matching variable before the campaign. Ask for a balance table. Large differences remaining mean the comparison is not fair.
The main weakness
Matching only handles measured factors. If exposed HCPs differ in ways not in the data, such as interest in the therapy area, results can be biased. Sensitivity analysis tests how much hidden bias would change conclusions. See sensitivity analysis.
When to use randomized designs instead
If you can randomly withhold media from part of the target list, do it. Randomized holdouts are the strongest design. See holdout test design. Matched designs are a reasonable choice when randomization is not feasible.
Evaluating vendor studies
Many firms offer matched-control studies, including measurement companies and media vendors. Evaluate any of them on:
- Matching variables and method.
- Balance table.
- Pre-period trend comparison.
- Confidence intervals.
- Sensitivity analysis.
- Whether the design was set before launch.
Common mistakes
- Matching on too few variables.
- No pre-period trend check.
- Treating matched results as causal certainty.
- Accepting results without a balance table.
Practical takeaway
Ask for the balance table and pre-period trends in every matched-control study. If exposed and control groups were already diverging before the campaign, the reported lift is not credible.
Frequently asked questions
What is a matched-control study?
A study comparing an exposed group with an unexposed group selected to look as similar as possible on factors that affect the outcome.
How is matching done?
Methods include exact matching on key variables, propensity score matching, and weighting. Each tries to make groups comparable before exposure.
Is a matched-control study as good as a randomized test?
Usually not. Randomization balances unmeasured factors too. Matched designs only balance what is measured.
Sources
- NIH, Principles and Practice of Clinical Research: Randomization concepts
- American Statistical Association, Statement on p-Values
- Veeva, Crossix
External guidance and platform documentation change. Links were current at publication; check them again before relying on them for a decision.
Editorial note. Analysis and frameworks are the author's own and do not represent Acxiom or any current or former employer, client, or named platform. Examples labeled hypothetical or illustrative are not results from real campaigns. Nothing here is legal, regulatory, or medical advice.
New pharma programmatic breakdowns, occasionally
One email when I publish something worth reading. Benchmarks, measurement teardowns, and case studies with the caveats attached. No cadence promises, no reselling your address.
Unsubscribe any time. See the privacy policy.
Working through this decision on a real plan?
I work on health and pharma data, identity, and activation, after five years running HCP and DTC programmatic agency-side. Happy to talk through how this applies to your situation.